To limit costs of genetic testing, we have proposed a testing strategy that involves paired germline and tumour BRCA1/2 testing in all patients diagnosed with epithelial ovarian cancer aged < 79 years old, while reserving tumour-first testing for those aged ≥ 80 years old [40]. The gene discussed is BRCA1; the disease is ovarian carcinoma.